Neuroendocrine tumors (NET) encompass a heterogeneous group of tumors demonstrating varied clinical behavior. The field has recently witnessed several important developments stemming from improvements in histopathological classification schemes, advanced imaging techniques, and a deeper understanding of the molecular mechanisms underlying tumor progression (in both sporadic and hereditary cancers). Platinum-based chemotherapy remains the mainstay of therapy for high grade carcinomas. In contrast, the treatment of advanced well-differentiated NET depends on site of origin, underlying tumor biology, and whether or not the patient is symptomatic. Somatostatin analogs continue to play a key role in controlling hormone-mediated symptoms. In addition, octreotide has demonstrated anti-tumor activity in midgut carcinoids. Novel somatostatin analogs (for use alone or in the context of peptide receptor radiotherapy or imaging) are on the horizon. Agents targeting VEGF-and mTOR-pathway signaling have been approved for pancreatic neuroendocrine tumors. In addition, two RET inhibitors have been approved for medullary thyroid cancer, evidence for a fundamentally new treatment paradigm (based on the use of targeted agents). Despite the advances, there remains a serious unmet need for additional treatment options for refractory high-grade neuroendocrine carcinomas, paragangliomas/pheochromocytomas, adrenocortical carcinomas, and progressive carcinoid tumors. Furthermore, the role of liver-directed therapy in the context of available systemic approaches needs clarification. Steady progress is anticipated, however, given the unprecedented number of ongoing clinical trials related to NET (including studies focused on symptom control, genetics, imaging, and novel therapies). Semin Oncol 40:4-22
T he last decade has witnessed major changes in our understanding of the genetics, classification, and treatment of neuroendocrine tumors (NET). These advances are especially important given that the incidence of NET is increasing, and the prevalence of the disease is even greater due to its relatively indolent nature. The classification schemes for NET have evolved considerably over the last decade, with changes in tumor nomenclature, an emphasis on the distinction between well-differentiated and poorly differentiated tumors, and routine incorporation of Ki67 as a proliferative marker. The basic premise that high-grade tumors should be treated according to small cell lung cancer algorithms remains unchanged. With respect to well-differentiated tumors, however, we now have a greater appreciation for the differences between pancreatic NETs and carcinoid tumors (which, in turn, may vary based on site of origin). This distinction has led to drastic changes in trial design, including stratification of patients according to site (if not exclusion of specific disease types altogether) and disease-specific drug approvals (eg, everolimus and sunitinib for pancreatic NETs). In short, our treatment paradigm for NET is changing, highlighting the fact that a "one size fits all" approach no longer applies in this disease.
HISTOPATHOLOGICAL CLASSIFICATION
The classification, grading, and staging systems for NET have evolved steadily over the several years. Updated guidelines have been proposed by numerous organizations, including the World Health Organization (WHO), the European Neuroendocrine Tumor Society (ENETS), the American Joint Committee on Cancer (AJCC), and the North American Neuroendocrine Tumor Society (NANETS). 1Ϫ4 While no standard scheme exists, modifications have largely aimed to establish standard terminology (especially for gastrointestinal NET) and incorporate proliferative index as fundamental component of grading, making a clear distinction between poorly differentiated and well-differentiated NET. Most recently, considerable energy has been dedicated to identifying minimum elements for pathology reports, such that any NET classification scheme can be applied.
In terms of nomenclature, except for tumors originating above the diaphragm, there has been a shift away from the term "carcinoid" in favor of the term "well-differentiated NET." In addition, organ-specific terms such as "islet cell tumor" and "insulinoma" are no longer commonly used. The 2010 WHO classification of tumors of the gastrointestinal tract, pancreas, and liver specifies that well-differentiated neuroendocrine neoplasms be classified as "neuroendocrine tumors." 4Ϫ6 Application of the descriptor "neuroendocrine carcinoma" is limited to high-grade (G3), poorly differentiated neoplasms (HGNEC). The family of HGNEC includes a number of subtypes, including extrapulmonary small cell carcinoma, a large cell variant, and an entity characterized by both small and large cell components. 5, 7 This classification system separates NETs into two clinically meaningful groups (G1/G2, well-differentiated NET v G3, poorly differentiated NET), which are characterized by vastly different behaviors and responses to therapy.
The proliferative rate figures heavily in all modern grading schemes and is generally assessed by counting mitotic figures or by calculating the percentage of cells labeled by immunohistochemistry for Ki67. 8Ϫ10 Controversy remains regarding the specific cutpoints used to delineate low-, intermediate-, and high-grade tumors. Furthermore, emerging data suggest that within the high-grade (G3) category (Ki67 Ͼ20%), there is a spectrum of clinical behavior suggesting that tumors with a Ki67 Ͻ55% may be less sensitive to chemotherapy and exhibit more indolent behavior. 11 The impact of these findings on future NET classification schemes and treatment algorithms remains to be determined. Furthermore, it is important to keep in mind that the value of the Ki67 is limited by the fact that the proliferative index can vary regionally throughout the tumor, leading to the potential for underestimating tumor grade based on a single biopsy. 12, 13 In addition, it can be a challenge to accurately assess the proliferative index when the sample is small (eg, fine-needle aspirate). 14 In terms of staging, a tumor-node-metastasis (TNM) staging system for NET was not included in the AJCC staging manual until 2010. 2 Additional classification systems exist. 15, 16 As such, future updates to the AJCC system are likely.
GENETICS OF NETS
While the majority of NETs are sporadic, several familial (inherited) syndromes account for the small subgroup of tumors that are inherited. Over the past two decades, numerous syndromes have been identified, with familial small intestinal NET and familial paraganglioma syndrome being the most recent additions.
Advances in our ability to analyze the molecular genetics of cancer have led to additional insights into the mechanisms underlying the development of sporadic NETs.
The majority of inherited tumors arise in the context of multiple endocrine neoplasia type 1 (MEN-1 syndrome), multiple endocrine neoplasia type 2 (MEN-2), von Hippel Lindau (VHL) syndrome, neurofibromatosis, and tuberosclerosis. 17Ϫ19 These syndromes are all relatively well characterized. MEN-1 syndrome occurs in the context of alterations in the MEN-1 gene, which encodes for the menin protein (which in turn binds dozens of protein partners). 19 MEN-2 can be divided into three clinical syndromes: MEN-2A, MEN-2B, and familial medullary thyroid cancer (FMTC). 18 Regardless of the clinical subtype, nearly 100% of affected families harbor a RET (rearranged during transfection) mutation. RET is a proto-oncogene that encodes for the RET transmembrane receptor tyrosine kinase (which binds members of the glial cell line derived neurotrophic factor 20 and activates PI3K/ AKT and RAS-dependent signaling). 21 Interestingly, specific RET mutations appear to dictate disease phenotype and tumor aggressiveness. 22 Germline mutations in RET account for 25% of patients with MTC and a small subgroup of patients presenting with pheochromocytoma. 23 In addition, somatic mutations of the RET proto-oncogene are occasionally found in sporadic pheochromocytomas and nearly half of sporadic MTCs (nearly all of these are the M918T mutation). 24, 25 Germline mutations in the VHL gene are distributed throughout the coding sequence and evident in nearly all families with VHL syndrome. 26 Renal cell carcinoma is the classic tumor type associated with VHL disease, but pancreatic NETs are also relatively common (identified in up to 15% of patients), and paragangliomas/ pheochromocytomas can occur. 25, 27 Of note, the exact molecular mechanism underlying the development of NET in VHL is unknown, but lack of degradation of hypoxia-inducible factor (HIF) in the absence of the VHL protein leads to upregulation of angiogenic factors (like vascular endothelial growth factor [VEGF]) presumably contributing to tumor growth. 28 A small subgroup of patients (Ͻ5%) with neurofibromatosis type 1 (NF1) develop catecholamine-producing tumors and/or NETs of the periampullary duodenum. 29 The NF1 gene encodes for the protein neurofibromin, which is known to inhibit the PI3K/AKT/mTOR pathway via suppression of RAS. 30 Tuberosclerosis genes TSC1 and TSC2 also are regulated by neurofibromin through mammalian target of rapamycin (mTOR) activation. 30 Interestingly, pheochromocytomas/paragan-gliomas are typically associated with NF1, whereas tuberosclerosis is linked to pancreatic NET. 17 While pancreatic NETs can occur in the setting of tuberosclerosis, neurofibromatosis, VHL syndrome, and MEN-1, most tumors are sporadic. The VHL gene is not mutated in sporadic pancreatic NETs, but whole exome sequencing suggests that MEN-1, DAXX/ATRX, and mTOR pathway gene alterations (including PTEN and TSC-2) are common. 31 Furthermore, gene expression profiling supports a role for PI3K/AKT/mTOR in sporadic pancreatic NETs, an observation that is of particular interest given the evidence that the mTOR inhibitor everolimus delays progression in these tumors. 32 Familial paraganglioma/pheochromocytoma is associated with NF1, MEN-2A, MEN-2B, and VHL syndrome but is most commonly seen in the setting of mutation of succinate dehydrogenase (SDHx) subunit genes (SDHB, SDHC, SDHD, SDHA, and SDHAF2), which encode portions of the mitochondrial complex II (an essential component of the electron transport chain and tricarboxylic acid cycle). 33, 34 SDHx genes are thought to function as tumor-suppressors, with loss of function leading to pseudo-hypoxia and angiogenesis. 34, 35 While speculative at present, these findings suggest that inhibitors of VEGF and/or HIF activity may have efficacy in tumors harboring SDH complex alterations. Other authors have suggested that loss of SDH function alters epigenetic processes (eg, methylation), leads to dysregulation of G-protein-coupled receptors, and/or genomic instability. 36, 37 Mutations in any of the genes abolish SDHx enzyme activity and leads to altered protein expression. 38 The loss of protein expression (especially with SDHB mutation) is the basis for emerging interest in using immunohistochemistry to screen for SDHx-related familial syndromes. 35, 38 Of note, the precise location of the SDHx subunit mutation can impact tumor distribution and whether or not the tumor is catecholamine-producing. Mutations in SDH assembly factor 2 (SDHAF2), which stabilizes SDHA, also have been recently identified, causing yet another form of familial paraganglioma (patients typically present with head and neck tumors). 39 The drivers underlying most truly sporadic pheoparagangliomas/paragangliomas remain unknown. 29 Alterations in SDH pathway function have been demonstrated to occur in sporadic tumors. Somatic deletions of SDH genes have been observed. 40 Occult germline mutations in SDH genes are also identified in over 20% of cases. 35, 41 Taken together, nearly 30% of cases of paraganglioma/pheochromocytoma occur in the setting of a hereditary cancer syndromes caused by a germline mutation. 38 As such, genetic testing should strongly be considered in patients younger than 45 years of age and/or with malignant, bilateral, or multifocal tumors.
Until recently, the genetic events leading to the development of ileal carcinoid were largely unknown.
Familial small intestinal NET is a rare syndrome that is inherited in an autosomal-dominant fashion and should be considered in patients with a compelling family history. While chromosome 18 alterations are relatively common in affected families, global gene expression profiles are not significantly different between sporadic and familial tumors, suggesting the possibility of a common pathogenic mechanism. 42 Loss of chromosome 18 is common in sporadic ileal carcioids, but other genetic events also have been described. 42Ϫ44 The pathogenesis of adrenal cortical carcinoma (ACC) remains somewhat of a mystery, as most tumors appear to be sporadic. Recent reports suggest that Sonic Hedgehog (Shh) and Wnt are mediators of adrenocortical lineage and organ homeostasis. 45 Constitutive activation of Wnt signaling due to loss-of-function mutations in the tumor-suppressor gene APC or gainof-function mutation in ␤-catenin frequently occurs in both adenomas and carcinomas, suggesting that Wnt pathway alterations are an early event in the oncogenic process. Loss of p53 might cooperate with additional genetic insults such as IGF2. 45 In summary, the last decade has witnessed advances in our understanding of the genetic alterations driving the development of NET. Understanding of the mutations underlying sporadic tumors have lagged behind that of familial tumors. Nevertheless, sequencing whole cancer cell genomes and other emerging laboratory techniques should provide should provide important clues regarding potentially novel therapeutic drug targets and the common genetic alterations in both familial and sporadic NET (Table 1) .
SOMATOSTATIN ANALOGS
Somatostatin receptor expression is typical for NETs and is the basis for the development and use of somatostatin analogs (SSTa) for the control of hormonemediated symptoms. 46 Octreotide was approved in the United States for this purpose in 1988, with a longacting version available shortly thereafter (lanreotide is approved in Europe for the control of hormone-mediated symptoms). While the availability of SSTa revolutionized the treatment of patients with carcinoid syndrome (controlling symptoms in approximately 70% of patients), some patients are intolerant of the drug and eventual resistance to therapy is common. 47Ϫ50 Recent data suggest that a robust biochemical response is only seen in approximately 40% of patients. 51 As such, much effort has been focused on identifying more efficacious somatostatin analogs, exploiting the fact that up to five different G-protein-coupled somatostatin receptors (SSTR1-5) are expressed in tumors, but octreotide and lanreotide primarily bind to SSTR-2 and Ϫ5. 52, 53 Although an antiproliferative effect of SSTa was suspected for years, it was not until the results of the PROMID study (Placebo-controlled, double-blind Randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine MIDgut tumors) that a cytostatic effect was documented in a prospective trial. 54 The data from this study suggest that octreotide delays progression in patients with advanced small bowel NETs. Importantly, the PROMID study did not address the optimal timing of therapy (up-front or at the time of disease progression). Furthermore, questions remain regarding the ideal dose of octreotide for antiproliferative effect, the cytostatic benefits of octreotide in NET arising outside of the small bowel, and its relative value in the setting of high tumor burden and/or G2 tumors. The potential activity of other SSTa is also unknown, although the results of the CLARINET study (Controlled study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors; a phase III trial in patients with nonfunctional mid-gut carcinoid tumors and pancreatic neuroendocrine tumors) should be available in the near future ( Table 2) .
Recent efforts have focused on the development of pan-receptor SSTa as a means of improving the control of tumor growth and/or hormone-mediated symptoms in neuroendocrine tumors. Pasireotide is an example of a pan-receptor SSTa with several fold higher affinity for SSTR-5, Ϫ3, and Ϫ1 compared to octreotide (but lower affinity for SSTR-2). 55 It is not yet known if the expanded binding affinity will translate into improved efficacy (either in the first-line or salvage setting after octreotide). The results of a randomized study in patients with refractory carcinoid syndrome are pending; several other trials assessing anti-tumor activity and/or symptom control are ongoing (Tables 2 and 3) .
Peptide receptor radiotargeted therapy (PRRT) is also under study. Used widely in Europe, PRRT exploits the expression of SSTR on NET as a means of delivering radiolabeled SSTa (using indium 111, yttrium 90, and/or lutettium 177 radionuclides). 56 This strategy is not readily available in the United States, largely due to the lack of prospective randomized trials demonstrating the value of PRRT relative to other available treatments (and the current paucity of centers with the expertise to administer this therapy). The primary toxicities associated with PRRT appear to be renal damage and bone marrow suppression, the severity of which may depend on the choice of SSTa, chelator, and/or radionuclide, number of cycles, radiation dose, and use of renal protective amino acid solutions. 57, 58 Randomized trials are planned; the results should lend important insight into the relative utility of this treatment strategy (Table 2) .
SYSTEMIC THERAPY FOR CARCINOID
Aside from somatostatin analogs, there are no systemic agents routinely used in the United States to treat carcinoid tumors. While commonly employed as an anti-tumor agent, octreotide is approved in the United Statesbased on its ability to treat hormone-mediated symptoms, not based on the results of the PROMID study. 54 Not surprisingly, the identification of agents with documented anti-tumor activity remains an area of intense interest. Octreotide affords symptom control and/or apparent anti-tumor activity in many patients, but additional strategies are desperately needed. As noted above, novel SSTa and PRRT are under study. 55, 56 Interferon is occasionally used (and is approved for this indication in Europe), owing more to its potential for inducing a biochemical response than a radiographic response. 59, 60 However, its toxicity limits its utility in common practice. Chemotherapy is of limited value, with response rates generally Ͻ20%. 61, 62 Recent data support the potential value of VEGF and/or mTOR as therapeutic targets in carcinoid. The results of phase II studies with oral inhibitors of VEGF receptor signaling suggest the potential for a cytostatic effect in carcinoid. 63, 64 Phase III studies are planned but have not yet been performed with this class of agent. Compelling results from a phase II study assessing octreotide long-acting release (LAR) plus bevacizumab or pegylated interferon were the basis for an ongoing phase III study in high-risk carcinoid (Southwest Oncology Group [SWOG]-0518). 65 Accrual to this study has been completed and the results are eagerly awaited. Numerous other anti-VEGF agents are under study in carcinoid (Table 4) .
The mTOR pathway also appears to be a potentially valid target in carcinoid. The results of the RADIANT-2 (RAD001 in Advanced Neuroendocrine Tumors) phase III study of everolimus plus octreotide LAR versus octreotide LAR plus placebo were confounded by informative censoring stemming from discordance between the local and central review. 66 There was a trend towards improved progression-free survival (PFS), but the results did not meet the predefined statistical boundary. As such, everolimus is not approved for this indication. The RADIANT-4 study recently opened and is designed to address the role of everolimus in nonfunctional progressive lung and gastrointestinal carcinoid tumors. Additional studies with mTOR inhibitors are ongoing (Table 4) .
Future clinical trials in carcinoid should be performed with careful consideration of the interpatient heterogeneity that characterizes the disease. 67 Given the difficulties related to imaging in carcinoid the primary endpoint should be chosen wisely, and the criteria for declaring radiographic response should be clear. Concurrent and/or previous exposure to octreotide should be taken into account, as should the extent of tumor progression at study entry. In addition, a subset analysis from the RADI-ANT-2 study suggests that other factors may impact outcome, including site of primary tumor, baseline chomogranin level, and distribution of metastatic disease (eg, bone metastases). 68 The relatively indolent nature of carcinoid is offset by the fact it has proven resistant to nearly every systemic agent tested. While widely used as an anti-tumor agent, the data in support of octreotide's cytostatic effect are fairly limited, and restricted to tumors originating in the small bowel or of unknown primary site. 54 The development of additional therapies has been confounded by inherent challenges related to studying carcinoid (eg, imaging, interpatient heterogeneity). Advances in our understanding of carcinoid tumor biology, coupled with a rational approach to clinical trial design, will hopefully facilitate the identification of novel therapeutic strategies and predictive markers to guide patient selection.
SYSTEMIC THERAPY FOR PANCREATIC NETS
In contrast to carcinoid, significant progress has been made in the development of novel treatments for pancreatic NETs over the past several years. Everolimus and sunitinib were both approved as single agents for the treatment of progressive pancreatic NET in 2011. Sunitinib is an oral tyrosine kinase inhibitor that inhibits a variety of kinases, including VEGF receptor-1 and-2, platelet derived growth factor receptor (PDGFR-alpha and -beta), colony-stimulating factor receptor Ϫ1, and Flt-3, and RET. 69 Accrual to the phase III trial was stopped before a pre-planned efficacy analysis, based on an analysis of enrolled patients suggesting that treatment with sunitinib was associated with improved PFS in patients with progressive pancreatic NET (11.4 months with sunitinib v 5.5 months with placebo; hazard ratio, 0.42; 95% confidence interval, 0.26Ϫ0.66; P Ͻ.001). 70 Consistent with a largely cytostatic effect, the objective response rate was only 9.3% (v 0% with placebo). The drug was generally well tolerated, the most frequent side effects being diarrhea, nausea, vomiting, asthenia, and fatigue. Treatment did not appear to adversely affect quality of life. Mature survival data are not yet available; however, the most recent analysis showed no significant difference between the two study arms (placebo patients had the option to receive sunitinib post-progression). 71 The mTOR inhibitor everolimus was compared to placebo in a phase III trial in patients with progressive pancreatic NET (the RADIANT-3 study). 72 Treatment with everolimus was associated with a significant improvement in PFS (11.6 v 4.6 months; hazard ratio, 0.35; logrank P Ͻ.0001) without improving overall survival (recognizing that the survival analysis was confounded by the cross-over design). Like sunitinib, the radiographic response rate was low, but the agent was relatively well tolerated. Since their approval in 2011, both agents have found a place in the treatment of patients with progressive pancreatic NET. However, the optimal sequence has not been defined, nor has the precise benefit of either agent in the setting of refractory disease. In addition, biomarkers predictive of response have yet to be identified but could prove important in the sequencing of therapies and/or selection of one agent over another. Importantly, work by Jiao et al suggest that only a minority of patients with pancreatic NET have tumors that harbor mutations in the mTOR pathway. 31 It is not yet known if such tumors are more likely to respond to everolimus. Given the recent validation of both mTOR and VEGF as targets for therapy in pancreatic NETs, the results of Cancer and Leukemia Group B (CALGB) 80701 (a phase II study exploring everolimus with or without bevacizumab in pancreatic NET) are keenly awaited (Table 4) .
In terms of other treatment options, numerous studies are ongoing (Tables 2 and 4 ). The results of the CLARI-NET study are highly anticipated and should provide insight into the anti-tumor efficacy of SSTa (lanreotide) in pancreatic NET. The role of PRRT and/or liver-directed therapy is similarly unclear, as prospective randomized studies have not been performed. Finally, much controversy surrounds the optimal chemotherapy regimen for pancreatic NETs. Typically reserved for patients with bulky disease or other situations when tumor regression would be ideal, several agents have been studied. While approved for use in pancreatic NETs, the value of streptozocin-based treatment is the subject of much debate, with response rates as low as 6% in some trials. 73, 74 That said, Kouvaraki et al reported the results of a retrospective study evaluating a three-drug regimen (streptozocin, 5-fluorouracil, doxorubicin) and demonstrating a 39% response rate in 84 patients. 75 More recently, temozolomide-based regimens have gained traction based on several small prospective and retrospective studies involving a variety of drug combinations, doses, and schedules. Most of the prospective studies suggest response rates in the 30%-45% range in pancreatic NETs. 76Ϫ78 In contrast, Strosberg et al reported a 70% response rate with capecitabine plus temozolomide in the first-line setting (based on retrospective data). 79 Data from randomized studies are lacking, but several studies are planned and/or ongoing (Table 4 ). In addition, studies validating the potential predictive value of O6-methylguanine DNA methyltransferase (MGMT) in patients treated with temozolomide are planned. 78, 80 
REGIONAL THERAPY FOR NETS
While resection is often curative in patients with localized well-differentiated NETs, its role in the treatment of patients with advanced disease remains controversial. Resection of the primary tumor in the setting of metastases may be associated with improved overall survival, particularly in patients with small bowel tumors. 81, 82 However, randomized trials are lacking. As such, in the asymptomatic patient, much depends on the morbidity of the planned procedure and the overall pace of the disease.
Resection or palliative debulking of liver metastases is also frequently considered in the patient with relatively stable disease. 83 Randomized controlled trials have not been performed, but the available data suggest the potential for improved hormone-mediated symptoms and improved overall survival in carefully selected patients. 84 Importantly, however, emerging data suggest that even R0 resections are not curative, with a recurrence rate of up to 99% at 10 years. 84 Despite the high risk of recurrence, there is no significant evidence to support the use of adjuvant therapy of any type post-resection.
Other liver-directed therapies are also widely used (eg, hepatic arterial embolization [HAE] or hepatic arterial chemoembolization [HAC]), with much attention recently focused on selective internal radiation therapy (SIRT) with 90 Y-labeled microspheres. 85, 86 Treatment appears to be relatively well tolerated, with radiographic response rates Ͼ50%. 87 Randomized trials are lacking, thus the benefit of SIRT relative to ablation, HAE, or HAC is unknown (Table 5) . Use of targeted agents as an adjunct to liver-directed therapy is another area of study. Ultimately, the risks and benefits of surgical intervention and other liver-directed therapies must be weighed carefully, with the goal of individualizing each patient's therapeutic plan, depending on extent and pace of disease, symptoms, and systemic treatment options. Trials aimed at definitively delineating the role of liver-directed treatments versus systemic treatments are needed.
ADVANCES IN UNUSUAL NETS
Historically, advanced MTC has proven extremely difficult to treat given its inherent resistance to chemotherapy. 88 Recently, however, expanding on the known link between RET mutation and MTC, the RET tyrosine kinase receptor has been validated as a target for therapy. 89 More than 300 patients with metastatic MTC were randomized to receive vandetanib (an oral tyrosine kinase inhibitor [TKI] targeting RET, VEGF receptor [VEGFR] , and the epidermal growth factor receptor [EGFR]) or placebo. Significant improvements in PFS (hazard ratio, 0.46; P Ͻ.001) and response rate (45% v 13%, P Ͻ.001) were noted, leading to US Food and Drug Administration approval for this indication in April 2011. While definitive conclusions could not be drawn, vandetanib appeared to have greater activity in patients harboring sporadic or germline RET mutations. Numerous other TKIs are also under investigation in MTC. 88, 90, 91 In fact, cabozantanib also recently received US Food and Drug Administration approval based on improved progression-free survival in patients with progressive MTC. 90 The value of these other agents compared to vandetanib and/or in the setting of vandetanib failure is unknown. Furthermore, the utility vandetanib in pheochromocytomas and/or paragangliomas harboring RET mutations is uncertain. Dedicated inhibitors of the mTOR pathway and/or VEGF signaling are also of potential interest in pheochromocytoma, paraganglioma, and MTC (Table 6 ). Adrenocortical carcinomas (ACCs) originate in the steroid-hormone producing adrenal cortex. Recent advances in diagnosis include immunohistochemical stains that may distinguish ACC from renal cell carcinoma, pheochromocytoma/paragangliomas, and other tumors. 92, 93 Emerging evidence suggests that malignant adrenocortical tumors are globally hypomethylated as compared with normal adrenal cortex and benign tumors. Methylation profile differences may also help to distinguish between primary benign and malignant adrenocortical tumors. 94 Treatment for this disease has remained fairly static over the past several years, with mitotane serving as the mainstay of therapy for advanced disease. Long awaited data from the FIRM-ACT study (First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment) were recently reported. 62 The FIRM-ACT trial was a randomized phase III trial of etoposide-doxorubicin-cisplatin (EDP)-mitotane versus streptozocin-mitotane in patients with advanced adrenocortical carcinoma. Patients with disease progression were offered the alternative regimen as second-line therapy. In the first line setting, patients receiving EDP-mitotane experienced a longer PFS (5.0 months v. 2.1 months; hazard ratio, 0.55; 95% confidence interval, 0.43 to 0.69; P Ͻ.001) and higher response rate (23.2% v 9.2%, P Ͻ.001) than those assigned to streptozocin-mitotane. There was no difference in overall survival, which was the primary endpoint of the study. Importantly, the rates of serious adverse events were no different between groups suggesting that EDP-mitotane is an option to consider in selected patients.
Not surprisingly, targeted therapy has emerged as an area of interest in ACC as additional treatment strategies are desperately needed (Table 7) . Several studies are ongoing exploring the utility of agents targeting the IGF-1R pathway signaling. Agents targeting other tyrosine kinases (including VEGFR and fibroblast growth factor receptor [FGFR] ) and inhibitors of mTOR signaling are also under evaluation. 95, 96 
HIGH-GRADE NEUROENDOCRINE CARCINOMAS
Despite the advances achieved in the treatment of well-differentiated NETs over the past several years, therapy for extrapulmonary HGNECs remains suboptimal. Patients almost always present with metastatic disease, and the median survival remains poor. 97, 98 Progress has been hampered by several factors, most notably the rarity of the disease, the potential for organ-specific differences in outcome, and the fact that the relatively rapid pace of disease limits accrual to clinical trials (eg, patients not eligible due to impaired end organ function, poor performance status, and/or need to initiate therapy urgently). As such, platinum-based chemotherapy remains the mainstay of therapy in patients with both localized and metastatic disease. Resection and/or radiation also play a role in selected patients, but even in apparently localized disease, eventual dissemination is likely. 98 Interestingly, while HGNECs are typically thought to represent an aggressive type of tumor within the NET spectrum, recent data suggest that these tumors may more closely resemble poorly differentiated carcinomas than well-differentiated NETs, suggesting a non-neuroendocrine cell lineage. 99 Support for a stem cell precursor in HGNEC comes from recent work suggesting that expression of nestin, a class VI intermediate filament protein expressed in stem/progenitor cells during central nervous system development, may be prognostic in patients with large cell neuroendocrine carcinoma of the lung. 100 The applicability of these finds to tumors that are extrapulmonary in origin is unknown.
Additional work is needed to characterize the pathogenesis and molecular features of HGNECs and to identify additional therapeutic targets. No standard therapy exists for treatment in the second line setting or beyond. 98 Small cell lung cancer regimens are commonly employed, and recent data suggest that temozolomide-based regimens may also be active in this setting. 101 The role of targeted agents in the treatment of HGNECs is unknown.
ADVANCES IN IMAGING
Neuroendocrine tumors can be difficult to reliably measure with conventional cross-sectional imaging. 67 The complications resulting from informative censoring in the RADIANT-2 trial in carcinoid exemplify this point. 66 Cases in which the local reviewer called progression prematurely (relative to the central reader) were censored, leading to a smaller number of events, and loss of power. This, coupled with the known limitations of other imaging modalities (eg, 111 In-DPTA-octreotdie scintigraphy), has fueled efforts to develop additional imaging tools with improved sensitivity and specificity. 102 Computerized tomography (CT) scans are routinely used to image NET. A noncontrast CT scan is of limited value when assessing primary tumors or hepatic lesions, which are best visualized as enhancing or hypervascular lesions on the early and late arterial phase images. 103 Recent advances in imaging include use of multi-detector CT, which allows appropriate arterial phase imaging. A multiphase scan (early, late arterial and portal venous) improves the sensitivity when imaging the liver and pancreas and is now considered standard procedure. 104, 105 Magnetic resonance imaging (MRI) is another valuable imaging modality for the detection and staging of NET. Imaging should be performed post-contrast in a dynamic and delayed fashion. 102, 105 Done properly, MRI may even offer better detection of liver metastases than CT. Diffusion-weighted imaging is a newer technique that has the potential to identify and characterize tumors. 106 One recent study suggested that differences in apparent diffusion characteristic (ADC) may be used to discriminate between well-differentiated and poorly differentiated NET. 107 Functional imaging may well hold the most promise in terms of yielding advances in the near future. For years, 111 In-DTPA octreotide scintigraphy has been the mainstay of functional imaging for NET. 56, 108 Combining conventional imaging with single-photon emission computerized tomography (SPECT) allows for better anatomical localization, particularly when performed in the context of hybrid SPECT-CT imaging. 109 However, the value of octreotide scintigraphy is limited by the dependence on SSTR-2 expression, uptake by non-neuroendocrine tumors and background binding in normal tissues. 110 Future improvements in somatostatin analog-based functional imaging are likely to stem from the use of newer analogs that have a higher affinity for SSTR-2 or wider spectrum of binding affinity. 56, 111 New chelators (eg, DOTA) are also under investigation, in part because they are more stable and may be used with other radionuclides (eg, 90 Y and 177 Lu) for PET imaging and PRRT (Table 8) .
Traditional PET scanning using 18 F-fluorodeoxyglucose has limited value in the assessment of well-differentiated NET but may be reasonable to consider in the setting of negative 111 In-octreotide scintigraphy and/or tumors with a high Ki67 proliferative index. 112 PET imaging using 18 F-fluoro-L-thymidine ( 18 F-flt) is also of interest, given its potential to assess tumor cell proliferation (DNA synthesis). However, its utility is limited by the fact that many well-differentiated NETs have a proliferation index that is below the level of detection. 113 While not widely available in the United States, there is significant interest in the use of gallium 68 -labeled somatostatin analogs for the detection of NETs (Table 8 ). In addition to potential improvements in image quality, PET scanning with 68 Ga-labeled somatostatin analogs affords the advantages of relatively short scanning time and low radiation exposure compared to traditional 111 In-DTPAoctreotide scintigraphy. 110, 114 Future advances in the functional imaging of NETs are likely to stem from the continued development of other novel PET imaging agents, including those based on serotonin or catecholamine precursors. 115, 116 
SUPPORTIVE CARE
Our ability to ameliorate the symptoms associated with NETs has improved over the years, owing in large part to the use of somatostatin analogs, improved techniques for decreasing tumor bulk, and advances in our understanding of NET biology. 117, 118 An assessment of tumor-associated and hormone-mediated symptoms should be a standard component of the care of these patients. In addition, the potential for treatment-related side effects (eg, nausea and myelosuppression from chemotherapy, hypertension and fatigue from sunitinib, steatorrhea from SSTa, and hyperlipidemia and mouth sores from everolimus) warrants consideration, particularly in the setting of chronic therapy with agents that are largely cytostatic. 70, 72, 119 In patients with functional tumors, acute hormonemediated symptoms and signs (eg, diarrhea, peptic symptoms, hypoglycemia, hypercalcemia) should be addressed, with somatostatin analogs often playing a major role. 47, 117, 118 The potential for long-term consequences of hormone excess or its treatment should also be considered (eg, carcinoid heart disease from serotonin excess, vitamin B 12 deficiency from chronic pharmacologic maintenance of the achlorhydric state, pancreatic insufficiency from octreotide). 119Ϫ121 In addition, careful attention should be paid to identifying the triggers of hormonemediated symptoms (eg, exercise and lack of frequent meals in the setting of insulin excess, or certain foods and stress in the setting of serotonin excess). 122 In the case of carcinoid syndrome specifically, use of a multidisciplinary team (eg, anesthesiologist, medical oncologist, surgeon, and/or cardiologist) to map out a plan for perioperative supportive care (eg, supplemental octreotide, colloid) can be instrumental in minimizing the risk of carcinoid crisis during an elective surgical procedure. 123Ϫ125 Future advances in supportive care for NETs are likely to stem from the identification of novel therapies and/or our ability to successfully debulk tumors. For example, in addition to general anti-tumor efficacy in pancreatic NETs, everolimus has been associated with improvement in symptoms related to insulin excess. 126 The precise value of targeted agents, PRRT, and specific chemotherapy regimens with respect to symptom control remains somewhat ill-defined, but is an area of intense interest. Selected symptomatic patients benefit from surgical debulking procedures for hepatic tumors, resulting in reduced pain and/or hormone-related symptoms. 127 As such, it is possible that advances in the area of liver directed therapies (eg, selective internal radiation therapy) will translate into improved palliation of symptoms, but randomized trials are needed. Surgical intervention for chronic obstruction and/or mesenteric ischemia associated with primary small bowel neuroendocrine tumors can also lead to a marked improvement in quality of life, thus should be a consideration in patients with otherwise indolent disease. 128 In terms of agents specifically designed for symptom palliation, a novel SSTa and a tryptophan hydroxylase inhibitor are under study. Pasireotide is one example of a SSTa with a broader spectrum of binding activity than octreotide that is currently being investigating in the setting of octreotide-refractory disease. 55, 129 Studies are ongoing to assess if the changes in binding specificity translate into improved symptom control and a favorable side effect profile. Telotristat etiprate (LX-166) is a novel agent designed to inhibit tryptophan hydroxylase, a key enzyme involved in serotonin biosynthesis. Preliminary data suggest that the orally bioavailable drug may have activity in patients with octreotide-refractory diarrhea related to carcinoid syndrome. 130 A phase III trial is planned ( Table 3) .
As additional agents with antitumor efficacy are identified, one important issue will be to minimize treatment related toxicity. For most well-differentiated NETs, treatment has proven to be cytostatic at best, requiring chronic therapy for relatively modest benefits. 54, 66, 70, 131 Thus, in a disease with survival measured in years, choice of agent, timing of initiation of therapy, and supportive measures to minimize treatment-related toxicity are important considerations.
SUMMARY
The last several years have witnessed remarkable advances in the area of NET. Novel imaging modalities have been developed, new drug targets have been identified for cancer treatment as well as symptom control, and there has been a major effort to understand the genetic changes underlying the development of both sporadic and familial tumors. Importantly, different subtypes of NET are now widely recognized, prompting major modifications to existing classification schemes and revolutionizing our approach to clinical trial design. A number of novel treatment strategies are under study (largely in carcinoid and pancreatic NETs), with two new agents approved for use in progressive pancreatic NETs (everolimus and sunitinib), as well as MTC (cabozantanib and vandetanib) in the last 2 years.
Despite remarkable progress in understanding the genetic alterations underlying paraganglioma and pheochromocytoma, little progress has been made in terms of systemic therapy. Similarly, progress in the treatment of high-grade NETs and ACCs is sorely lacking. Ongoing research aimed at understanding the molecular events underlying disease progression will hopefully lead to improved outcomes in these patients.
